Receptor and Transporter Imaging Studies in Schizophrenia, Depression, Bulimia and Tourette's Disorder—Implications for Psychopharmacology-

Summary: Considerable progress has been achieved over the past 15 years in uncovering the biological basis of major psychiatric disorders. To determine patterns of brain dysfunction and to uncover the mechanism of action of centrally active compounds we used single photon emission computerized tomography (SPECT) as well as positron emission tomography (PET) in patients diagnosed with schizophrenia, depression, bulimia and Tourette's disorder. Striatal D2 and 5-HTIA receptors were studied in schizophrenia and 5-HT transporters (5-HTT) in depression and bulimia. Patients were either drug-naive or drug free, or we studied the influence of specifically acting compounds on receptor/transporter occupancy. We could demonstrate that atypical antipsychotics have a dose-dependent (with the exception of clozapine and quetiapine) lower striatal D2 receptor occupancy rate compared with typical neuroleptics, paralleling the more favourable extrapyramidal side effects of atypical antipsychotics. However, no association between striatal D2 receptor occupancy rates and antipsychotic efficacy has been found. The measurement of S-HTIA receptors in drug-naïve schizophrenic patients using the in vivo PET methodology revealed an increase of cortical 5-HTIA receptor binding potential in schizophrenia. β-CIT as a ligand for measurement of 5-HT transporter densities (5-HTT) revealed lower rates in depression compared to age-and sex-matching healthy controls, a measurement that has also been obtained for bulimia. We also documented seasonal variations in brain serotonergic function by our finding of reduced brain 5-HTT availability in winter (compared to summer) in healthy controls. Furthermore, displaceable [124I]/β-CIT binding in the area corresponding to the left striatum (representing predominantly the density of dopamine transporters) was significantly reduced in SAD patients compared to healthy controls. In depression as well as in bulimia, selective serotonin reuptake inhibitors significantly decreased the β-CIT binding potential, however, no significant dose relationship has been obtained in depression. Genotyping depressed patients for the serotonin transporter promoter gene region (5-HTTLPR) did not provide evidence for in vivo functional regulation of 5-HTT availability by 5-HTTLPR in the thalamus-hypothalamus and mesencephalon-pons of healthy subjects. In patients suffering from Tourette's disorder (TD) we were unable to detect differences of dopamine transporter densities between psychotropic drug-naïve TD patients and controls. Furthermore, no difference could be found between currently treated (with antipsychotics) and psychotropic drugnaive TD patients. Our data provide insight into the pathophysiology of neuropsychiatric disorders and may guide future psychopharmacological drug developments.

[1]  P. Fischer,et al.  In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol , 1999, Psychopharmacology.

[2]  L. Deecke,et al.  Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric Disorders , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  L. Farde,et al.  Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. , 1998, Archives of general psychiatry.

[4]  Kurt Hornik,et al.  No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism , 2001, Biological Psychiatry.

[5]  Alexander Neumeister,et al.  Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2β-carbomethoxy-3β- (4-iodophenyl)tropane and single photon emission computed tomography , 2000, Biological Psychiatry.

[6]  S. Kasper,et al.  In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment , 1999, European Neuropsychopharmacology.

[7]  C. Halldin,et al.  A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects , 1997, Neuropsychopharmacology.

[8]  R Felix,et al.  Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease. , 1991, European journal of radiology.

[9]  S. Kasper,et al.  P-4-32 IBZM-SPECT and D2 dopamine receptor occupancy: Different profiles with atypical neuroleptics , 1995, European Neuropsychopharmacology.

[10]  F. Tarazi,et al.  Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  S. Kasper,et al.  IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol , 1997, Psychopharmacology.

[12]  P. Seeman,et al.  Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. , 1999, The American journal of psychiatry.

[13]  Marc Laruelle,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.

[14]  S. Montgomery,et al.  The optimal dosing regimen for citalopram‐a meta‐analysis of nine placebo‐controlled studies , 1994, International clinical psychopharmacology.

[15]  S. Moncada.  Silent 5-HT A receptor antagonists: utility as research tools and therapeutic agents , 1993 .

[16]  S. Kapur,et al.  O-12-8 Risperidone and the relationship between D2 receptor occupancy and plasma levels , 1996, European Neuropsychopharmacology.

[17]  S. Tejani-butt.  [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. , 1992, The Journal of pharmacology and experimental therapeutics.

[18]  Alexander Neumeister,et al.  [123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder , 2000, Biological Psychiatry.

[19]  R. Baldessarini,et al.  N-substituted analogs of 2 beta-carbomethoxy-3 beta- (4'-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. , 1996, Journal of medicinal chemistry.

[20]  H. Meltzer,et al.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia , 2004, Psychopharmacology.

[21]  S. Kasper,et al.  [123I] β-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa , 2001, Biological Psychiatry.

[22]  Victor W. Pike,et al.  Remotely-controlled production of the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635, via 11C-carboxylation of an immobilized Grignard reagent , 1996 .

[23]  S. Houle,et al.  Imaging the 5-HT(1A) receptors with PET: WAY-100635 and analogues. , 2000, Nuclear medicine and biology.

[24]  Alan A. Wilson,et al.  Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. , 2002, Archives of general psychiatry.

[25]  Robert B. Innis,et al.  Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  S. Kasper,et al.  Quetiapine: efficacy and tolerability in schizophrenia , 2001, European Neuropsychopharmacology.

[27]  S. Kasper,et al.  IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. , 1998, European psychiatry : the journal of the Association of European Psychiatrists.

[28]  S. Kasper,et al.  Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol , 2002, Psychopharmacology.

[29]  C. Divgi.  All of the above (with caveats for each). , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Ralph Myers,et al.  Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.

[31]  C Burger,et al.  A JAVA environment for medical image data analysis: initial application for brain PET quantitation. , 1998, Medical informatics = Medecine et informatique.

[32]  C. Halldin,et al.  Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. , 1995, Journal of clinical psychopharmacology.

[33]  M. Millan,et al.  Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors , 1996, Neuropharmacology.

[34]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[35]  J. Kornhuber,et al.  Binding kinetics in the human brain , 2022 .

[36]  R. M. Murray,et al.  Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia , 1992, The Lancet.

[37]  Shitij Kapur,et al.  Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET , 2001, Neuropsychopharmacology.

[38]  C. Halldin,et al.  Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain , 1994, Synapse.

[39]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[40]  Abraham Weizman,et al.  Serotonergic agents in the treatment of acute neuroleptic‐induced akathisia: open‐label study of buspirone and mianserin , 1997, International clinical psychopharmacology.

[41]  B. Långstrom,et al.  Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 MG ‘seroquel’ TID , 1996, Schizophrenia Research.

[42]  S. Kasper,et al.  Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[43]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[44]  E. Rüther,et al.  Unerwünschte Wirkungen von Psychopharmaka , 1994 .

[45]  C. Dourish,et al.  Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. , 1993, Trends in pharmacological sciences.

[46]  S. Kasper,et al.  Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone , 1996, Psychiatry Research: Neuroimaging.

[47]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[48]  B. Långstrom,et al.  P-4-65 Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg Seroquel™ tid , 1995, European Neuropsychopharmacology.

[49]  S. Kasper,et al.  63-2 Sertindole and dopamine D2 receptor occupancy , 1997, Biological Psychiatry.

[50]  J. Baron,et al.  In Vivo Assay for Neuroleptic Receptor Binding in the Striatum , 1987, British Journal of Psychiatry.

[51]  S. Kapur,et al.  Serotonin-dopamine interaction and its relevance to schizophrenia. , 1996, The American journal of psychiatry.

[52]  S. Kasper,et al.  Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls , 2001, Psychological Medicine.

[53]  C. Halldin,et al.  Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs , 1996, British Journal of Psychiatry.

[54]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[55]  Siegfried Kasper,et al.  New aspects of diagnosis and pharmacotherapy of eating disorders. , 1997, International journal of psychiatry in clinical practice.

[56]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[57]  S. Kasper,et al.  P.2.069 123I IBZM spect imaging of dopamine-2 receptors in psychotic patients treated with zotepine , 1997, European Neuropsychopharmacology.

[58]  C. Tanaka,et al.  Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. , 1991, Life sciences.

[59]  Eva Meisenzahl,et al.  In vivo effects of olanzapine on striatal dopamine D2/D3 receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study , 1999, European Journal of Nuclear Medicine.

[60]  S. Kasper,et al.  IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics , 1998, European Psychiatry.

[61]  S. Kasper,et al.  Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine , 1997, Psychopharmacology.

[62]  Linda Carpenter,et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.

[63]  S. Asenbaum,et al.  Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics , 1992, The Lancet.

[64]  S. Kapur,et al.  High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. , 1996, The American journal of psychiatry.

[65]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[66]  P B Hoffer,et al.  [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. , 1991, Journal of medicinal chemistry.

[67]  S. Kasper,et al.  Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol – a 123I-IBZM SPECT study , 1998, Psychopharmacology.

[68]  R. Baldessarini,et al.  N-Substituted Analogs of 2β-Carbomethoxy-3β-(4‘-iodophenyl)tropane (β-CIT) with Selective Affinity to Dopamine or Serotonin Transporters in Rat Forebrain , 1996 .

[69]  Robert B. Innis,et al.  Development and Reliability of a Method for Using Magnetic Resonance Imaging for the Definition of Regions of Interest for Positron Emission Tomography. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[70]  D. Goff,et al.  An open trial of buspirone added to neuroleptics in schizophrenic patients. , 1991, Journal of clinical psychopharmacology.

[71]  G. Sedvall,et al.  D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. , 1995, The American journal of psychiatry.

[72]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[73]  J Tauscher,et al.  Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  H. Möller,et al.  [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. , 1996, The American journal of psychiatry.

[75]  S. Kasper,et al.  No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette’s disorder patients: a [123I]-β-CIT SPECT-study , 2001, European Neuropsychopharmacology.

[76]  Alan A. Wilson,et al.  5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. , 1998, The American journal of psychiatry.

[77]  S. Kapur,et al.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. , 2001, The American journal of psychiatry.